Comprehensive histologic analysis of ALK-rearranged lung carcinomas

American Journal of Surgical Pathology

Volumn 35, Issue 8, 2011, Pages 1226-1234

  Yoshida, Akihiko ^a,c   Tsuta, Koji ^a   Nakamura, Harumi ^a   Kohno, Takashi ^d   Takahashi, Fumiaki ^f   Asamura, Hisao ^b   Sekine, Ikuo ^a   Fukayama, Masashi ^c   Shibata, Tatsuhiro ^e   Furuta, Koh ^a   Tsuda, Hitoshi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b Division of Thoracic Surgery   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d Division of Genome Biology   (Japan)

^e NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^f KITASATO UNIVERSITY   (Japan)

Author keywords

adenocarcinoma; EML4 ALK; histomorphology; lung

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; PROTEIN TYROSINE KINASE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; ENZYMOLOGY; FEMALE; GENE REARRANGEMENT; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG TUMOR; LYMPH NODE; LYMPH NODE METASTASIS; MALE; METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PLEURA TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PLEURAL NEOPLASMS; PNEUMONECTOMY; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79961099514     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3182233e06     Document Type: Article

References (23)

1. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3:13-17.
2. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009;22:508-515.
3. Jokoji R, Yamasaki T, Minami S, et al. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J Clin Pathol. 2010;63:1066-1070.
4. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693-1703.
5. Mano H. Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci. 2008;99:2349-2355.
6. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008;32: 810-827.
7. Nielsen TO, West RB. Translating gene expression into clinical care: sarcomas as a paradigm. J Clin Oncol. 2010;28:1796-1805.
8. Nitta H, Zhang W, Kelly BD, et al. Automated brightfield breakapart in situ hybridization (ba-ISH) application: ALK and MALT1 genes as models. Methods. 2010;52:352-358.
9. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995;75:2844-2852.
10. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500. (Pubitemid 38720929)
11. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101:13306-13311. (Pubitemid 39209661)
12. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27: 157-172; discussion 207-212. (Pubitemid 351193639)
13. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009;15: 5216-5223.
14. Shiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood. 1995;86:1954-1960.
15. Sobin L, Wittekind C, ed. International Union Against Cancer (UICC) TNM Classification of Malignant Tumours. 6th ed. New York: Wiley-Liss; 2002.
16. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561-566. (Pubitemid 47206930)
17. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009;15:3143-3149.
18. Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004.
19. Wu M, Orta L, Gil J, et al. Immunohistochemical detection of XIAP and p63 in adenomatous hyperplasia, atypical adenomatous hyperplasia, bronchioloalveolar carcinoma and well-differentiated adenocarcinoma. Mod Pathol. 2008;21:553-558. (Pubitemid 351589661)
20. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol. 2002;26:767-773. (Pubitemid 34546942)
21. Yatabe Y, Koga T, Mitsudomi T, et al. CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas. J Pathol. 2004;203:645-652. (Pubitemid 38714101)
22. Yoshida A, Tsuta K, Watanabe S, et al. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer. 2011;72:309-315.
23. Yoshida A, Tsuta K, Nitta H, et al. Bright-field Dual Color Chromogenic In situ Hybridization for Diagnosing EML4-ALKpositive Lung Adenocarcinomas. J Thorac Oncol. 2011. (In Press).